Five-year follow-up of secondary iris-claw intraocular lens implantation for the treatment of aphakia: Anterior chamber versus retropupillary implantation.
Aged
Anterior Chamber
/ physiopathology
Aphakia
/ physiopathology
Cornea
/ physiopathology
Endothelial Cells
/ pathology
Eye
/ physiopathology
Female
Humans
Iris
/ physiopathology
Lens Implantation, Intraocular
/ methods
Lens, Crystalline
/ physiopathology
Lenses, Intraocular
Male
Ophthalmologic Surgical Procedures
/ methods
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
30
09
2018
accepted:
07
03
2019
entrez:
11
4
2019
pubmed:
11
4
2019
medline:
20
12
2019
Statut:
epublish
Résumé
Though several procedures of IOL implantation have been described (sutured scleral fixation, intra-scleral fixation, angle-supported anterior chamber, and anterior chamber or retropupillary iris-claw IOLs), there are no randomized trials which are comparing different techniques. Hence, the surgical treatment of aphakia still remains controversial and challenging. The purpose of this study was to compare the long-term efficacy and the rate of complications of anterior versus posterior Iris-claw intraocular lenses (IOL) implantation to correct for the treatment of aphakia without sufficient capsule support. Consecutive eyes having secondary implantation of aphakic iris-fixated IOLs with a follow-up of at least 5 years were considered. Mean correct distance visual acuity (CDVA) changes, percentage of eyes with CDVA improvement, mean corneal endothelial cell density (CECD) loss and the rate of other complications were used for statistical analysis. The study evaluated a total of 180 eyes (Group A: 87 anterior chamber iris-claw fixation, Group B: 93 retropupillary iris-claw implantation) of 180 consecutive different patients, with aphakia of various reasons. CDVA improved significantly in both groups after surgery (P<0.001, ANOVA), and was remarkably higher than baseline in both groups from first week and during the entire follow-up (P<0.001, Tukey's Honest Significant Difference). There was no statistically significant difference in CDVA between the two groups during each follow-up visits (P = NS, unpaired t-test) and in the CDVA improvement percentage between the two groups (P = 0.882, Chi-square test). No significant changes in CECD were noted after surgery in both groups (ANOVA Group A: P = 0.067, Group B: P = 0.330P). No intra-operative complications occurred in both groups. There was no statistically significant difference in the rate of complications between the two groups (P = NS, Chi-square test), except for pigment precipitates which were higher in Group A (P<0.05, Chi-square test). Five-year follow-up shows that secondary implantation of aphakic IOLs is effective and safe for the correction treatment of aphakia in eyes without capsule support.
Sections du résumé
BACKGROUND
Though several procedures of IOL implantation have been described (sutured scleral fixation, intra-scleral fixation, angle-supported anterior chamber, and anterior chamber or retropupillary iris-claw IOLs), there are no randomized trials which are comparing different techniques. Hence, the surgical treatment of aphakia still remains controversial and challenging. The purpose of this study was to compare the long-term efficacy and the rate of complications of anterior versus posterior Iris-claw intraocular lenses (IOL) implantation to correct for the treatment of aphakia without sufficient capsule support.
METHODS AND FINDINGS
Consecutive eyes having secondary implantation of aphakic iris-fixated IOLs with a follow-up of at least 5 years were considered. Mean correct distance visual acuity (CDVA) changes, percentage of eyes with CDVA improvement, mean corneal endothelial cell density (CECD) loss and the rate of other complications were used for statistical analysis. The study evaluated a total of 180 eyes (Group A: 87 anterior chamber iris-claw fixation, Group B: 93 retropupillary iris-claw implantation) of 180 consecutive different patients, with aphakia of various reasons. CDVA improved significantly in both groups after surgery (P<0.001, ANOVA), and was remarkably higher than baseline in both groups from first week and during the entire follow-up (P<0.001, Tukey's Honest Significant Difference). There was no statistically significant difference in CDVA between the two groups during each follow-up visits (P = NS, unpaired t-test) and in the CDVA improvement percentage between the two groups (P = 0.882, Chi-square test). No significant changes in CECD were noted after surgery in both groups (ANOVA Group A: P = 0.067, Group B: P = 0.330P). No intra-operative complications occurred in both groups. There was no statistically significant difference in the rate of complications between the two groups (P = NS, Chi-square test), except for pigment precipitates which were higher in Group A (P<0.05, Chi-square test).
CONCLUSIONS
Five-year follow-up shows that secondary implantation of aphakic IOLs is effective and safe for the correction treatment of aphakia in eyes without capsule support.
Identifiants
pubmed: 30970023
doi: 10.1371/journal.pone.0214140
pii: PONE-D-18-28487
pmc: PMC6457484
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0214140Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Eur J Ophthalmol. 2015 May-Jun;25(3):208-13
pubmed: 25363856
J Cataract Refract Surg. 2018 Jul;44(7):818-826
pubmed: 30055690
Am J Ophthalmol. 2006 Feb;141(2):308-312
pubmed: 16458685
Am J Ophthalmol. 2004 Nov;138(5):723-31
pubmed: 15531305
J Cataract Refract Surg. 1998 Aug;24(8):1039-49
pubmed: 9719962
Klin Monbl Augenheilkd. 2008 Dec;225(12):1041-4
pubmed: 19085782
J Cataract Refract Surg. 2007 Mar;33(3):455-64
pubmed: 17321397
J Refract Corneal Surg. 1994 Sep-Oct;10(5):565-70
pubmed: 7530107
J Cataract Refract Surg. 2005 Dec;31(12):2266-71
pubmed: 16473216
Ger J Ophthalmol. 1993 Apr;2(2):70-5
pubmed: 8485442
Ophthalmology. 2017 Aug;124(8):1136-1142
pubmed: 28457613
Eur J Ophthalmol. 2003 Aug-Sep;13(7):627-33
pubmed: 14552597
J Cataract Refract Surg. 2011 May;37(5):866-72
pubmed: 21419596
Br J Ophthalmol. 2009 Oct;93(10):1273-5
pubmed: 19778986
Ophthalmic Surg. 1992 Jul;23(7):496-8
pubmed: 1407951
Korean J Ophthalmol. 1991 Jun;5(1):42-6
pubmed: 1942602
Ophthalmology. 1995 Feb;102(2):211-6
pubmed: 7862409
Int J Ophthalmol. 2014 Apr 18;7(2):283-7
pubmed: 24790871
J Cataract Refract Surg. 2007 Jul;33(7):1341-2
pubmed: 17586400
J Cataract Refract Surg. 2003 Feb;29(2):301-8
pubmed: 12648641
Acta Ophthalmol (Copenh). 1993 Aug;71(4):482-6
pubmed: 8249578
Br J Ophthalmol. 2009 Oct;93(10):1301-6
pubmed: 19416933
J Cataract Refract Surg. 1996 Dec;22(10):1476-84
pubmed: 9051506
Eye (Lond). 1991;5 ( Pt 6):694-8
pubmed: 1800168
Retina. 2010 Jan;30(1):131-9
pubmed: 19834354
J Cataract Refract Surg. 1998 Jul;24(7):945-50
pubmed: 9682115
Indian J Ophthalmol. 2016 Jan;64(1):45-9
pubmed: 26953023
Ophthalmologe. 2002 Jul;99(7):580-3
pubmed: 12148307
J Cataract Refract Surg. 1994 Jan;20(1):34-9
pubmed: 8133477
Eye (Lond). 2011 Jan;25(1):73-6
pubmed: 20948556
Ophthalmology. 2018 Apr;125(4):486-494
pubmed: 28935401
Br J Ophthalmol. 2014 May;98(5):658-63
pubmed: 24489374
J Cataract Refract Surg. 2012 Sep;38(9):1595-601
pubmed: 22906445
J Cataract Refract Surg. 2000 Aug;26(8):1163-71
pubmed: 11008043
Graefes Arch Clin Exp Ophthalmol. 2009 Apr;247(4):457-62
pubmed: 18787833
Ophthalmology. 2003 Apr;110(4):840-59
pubmed: 12689913
BMC Ophthalmol. 2015 Oct 27;15:143
pubmed: 26507387
J Cataract Refract Surg. 2012 Dec;38(12):2139-43
pubmed: 23036355
J Refract Surg. 2002 Nov-Dec;18(6):697-707
pubmed: 12458863
J Cataract Refract Surg. 2011 Sep;37(9):1667-72
pubmed: 21855764
Am J Ophthalmol. 2007 Oct;144(4):586-91
pubmed: 17692274
Ophthalmologica. 2010;224(5):283-90
pubmed: 20332652
In Vivo. 2016 11-12;30(6):733-738
pubmed: 27815455
J Refract Surg. 2011 Oct;27(10):729-35
pubmed: 21710953
Am J Ophthalmol. 2007 Sep;144(3):371-377
pubmed: 17624290
J Cataract Refract Surg. 1993 Jul;19(4):488-93
pubmed: 8355155
Curr Opin Ophthalmol. 2001 Feb;12(1):47-57
pubmed: 11150081
Ophthalmology. 1993 Nov;100(11):1636-9
pubmed: 8233388
J Cataract Refract Surg. 2018 Oct;44(10):1186-1191
pubmed: 30122352